MedLife is an integrated provider of healthcare services in Romania able to accompany the patient across the entire medical journey from prevention to diagnosis to treatments in clinics and hospitals. We expect the company to continue to capitalise on the growth of private healthcare spending in Romania. The current valuation of 9.5x 2026e EV/EBITDA is in line with its peers, while we project EBITDA growth of 16% p.a. until 2027e compared to high single digit growth for peers. We are therefore i...
A director at Med Life SA sold 2,000,000 shares at 6.750RON and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
EME Equity Market – May 2025 EME indices mostly in the green in May, apart from Türkiye. The MSCI EM Europe Index added 3.6% mom in EUR and USD terms. The Greek ASE index (+7.8% mom) was the best performer, followed by the Czech PX (+6.6% mom) and Romanian BET indices (+5.0% mom), the Hungarian BUX (+4.0% mom) and the Polish WIG20 (+2.0% mom; all in EUR terms). The Turkish ISE30 Index was, again, the worst performer, with a more modest decline (-1.4% mom in EUR terms) this time.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.